Prof. Zhen Hu 胡震
Chief Physician, Professor
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of breast cancer, including mastectomy, breast-conserving surgery, oncoplastic procedures, and breast reconstruction. Diagnosis, prevention, and treatment of hereditary breast cancer.
Dr. Hu is a Chief Physician, Professor, and Master’s supervisor. Dr. Hu earned a PhD in Oncology in 2003. Training includes study at the University of California, Los Angeles (2002), MD Anderson Cancer Center (2009), and Dana-Farber Cancer Institute (2009).
Professional roles
- Member, Oncoplastic Surgery Committee, China Anti-Cancer Association
- Standing Committee Member, Familial Hereditary Tumor Committee, China Anti-Cancer Association
- Standing Committee Member, Breast Disease Committee, China Medical Education Association
- Standing Committee Member, Breast Disease Committee, International Exchange and Promotion Association for Medical Health Care
Name order: in Chinese the family name comes first (Hu Zhen). Papers usually list the name as Zhen Hu or Hu Z.
Selected publications
17 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- MedComm (2020), 2026 (senior author): Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD-1 Inhibitor and Niraparib in GErm-Line-mutAted Metastatic Breast Cancer. PubMed 41930344
- Pathophysiology, 2026 (senior author): Novel Insights into the Enigmatic Genetics of Male Breast Cancer in China. PubMed 41718387
- Oncol Ther, 2025 (first author): Real-World Epidemiology, Clinical Characteristics and Outcomes of Women with Germline BRCA Mutation and Early Breast Cancer in China. PubMed 41139350
- Cancer Pathog Ther, 2025 (senior author): Breast cancer risk associated with BRCA1 and BRCA2 pathogenic variants in the Eastern Chinese population. PubMed 40182128
- Gland Surg, 2021 (senior author): The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer. PubMed 33633982
- Gene, 2020 (senior author): The frequency of PTEN germline mutations in Chinese breast cancer patients: The PTEN gene may not be closely associated with breast cancer in the Chinese population. PubMed 32234455
- Hereditas, 2020 (senior author): Profiling of the germline mutation BRCA1: p.Ile1845fs in a large cohort of Han Chinese breast cancer. PubMed 31908633
- J Breast Cancer, 2018 (senior author): Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations. PubMed 30275858
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion